Patents
Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
09/2004
09/08/2004EP1454634A1 Preparation compositions containing acid-unstable physiologically acitve compounds and process for producing the same
09/08/2004EP1454631A1 Oral insulin composition and methods of making and using thereof
09/08/2004EP1454630A1 Long acting injectable insulin composition and methods of making and using thereof
09/08/2004EP1454624A1 Antiviral, antibacterial pharmaceutical composition of cantharidic anhydride and method of preparation thereof
09/08/2004EP1453963A2 A structure for presenting desired peptide sequences
09/08/2004EP1453916A2 Novel combination containing a poloxamer and chondroitin sulphuric acid and/or a glycoprotein and use thereof
09/08/2004EP1453909A1 Cereal beta glucan compositions, methods of preparation and uses thereof
09/08/2004EP1453859A2 Chemically-modified human growth hormone conjugates
09/08/2004EP1453855A1 Antimicrobial bolisin peptides
09/08/2004EP1453845A2 Compositions of nucleic acids and cationic aminoglycosides and methods of using and preparing the same
09/08/2004EP1453841A1 Technetium or rhenium complexes, radiopharmaceutical products comprising them
09/08/2004EP1453837A2 Targeted therapeutics and uses thereof
09/08/2004EP1453816A2 Phenoxy amine compounds and compositions for delivering active agents
09/08/2004EP1453598A1 Method for preparing a multiple water/oil/water emulsion
09/08/2004EP1453546A2 Treatment of angiogenesis disorders using targeted nanoparticles
09/08/2004EP1453545A1 Water-soluble polymer conjugates of retinoic acid
09/08/2004EP1453544A2 Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors
09/08/2004EP1453542A1 Nutraceutical composition
09/08/2004EP1453537A1 Composition for viral preservation
09/08/2004EP1453536A1 Composition for the preservation of viruses
09/08/2004EP1453525A1 Selective targeting of apoptotic cells
09/08/2004EP1453523A1 Heparin-containing ophthalmic agent
09/08/2004EP1453519A2 Aqueous ifosfamide composition
09/08/2004EP1453517A1 Platinum derivative pharmaceutical formulations
09/08/2004EP1453508A1 Tempamine compositions and use against cellular oxidative damage
09/08/2004EP1453502A2 Pharmaceutical formulations comprising indolinone derivatives
09/08/2004EP1453489A2 Acetaminophen compositions
09/08/2004EP1453487A1 Pharmaceutical dosage form with multiple coatings
09/08/2004EP1453485A2 Matrices for stabilizing and controlled release of problematic substances
09/08/2004EP1453483A2 High-concentration lidocaine compositions and methods for their preparation
09/08/2004EP1453481A1 Reverse-micellar delivery system for controlled transportation and enhanced absorption of agents
09/08/2004EP1453447A1 Composition and transdermal drug delivery device
09/08/2004EP1453446A1 Nitric oxide releasing eptfe coated medical device sandwich
09/08/2004EP1347744B1 Solid dispersions of nitrate active principles
09/08/2004EP1326624B1 Method for producing phyllanthus extracts
09/08/2004EP1292281B1 Novel tiotropium-containing inhalation powder
09/08/2004EP1225897B1 Composition for treatment of constipation and irritable bowel syndrome
09/08/2004EP1189579B1 Gelled aqueous cosmetic compositions
09/08/2004EP1077669B1 Cosmetic product
09/08/2004EP1075281B1 Polyol-ifn-beta conjugates
09/08/2004EP1039874B1 Compositions and methods for treatment of alopecia
09/08/2004EP1014954B9 Transdermal therapeutic system
09/08/2004EP0975370B9 Composition and method for enhancing transport across biological membranes
09/08/2004EP0758232B1 Methods for modulating t cell responses by manipulating intracellular signal transduction
09/08/2004CN1527839A Modified human brain-derived neutrophic factor (BDNF) with reduced immunogenicity
09/08/2004CN1527729A Topical pharmaceutical formulation
09/08/2004CN1527727A Improved chelator conjugates
09/08/2004CN1527726A Conjugates of erythropoietin (PEP) with polyethylene glycol (PEG)
09/08/2004CN1527724A Liquid formulation comprising cetuximab and a fatty acid ester of polyoxyethylene sorbitan
09/08/2004CN1527716A Anti-virus agent
09/08/2004CN1527714A Pharmaceutical composition and method for treating hypogonadism
09/08/2004CN1527706A Pharmaceutical compositions containing terbinafin and use thereof
09/08/2004CN1527705A Pharma ceutical formulation containing and LTB4 antagonist
09/08/2004CN1527701A Tablets quickly disintegrated in oral cavity
09/08/2004CN1527700A Compaction process for manufacture of sodium phenytoin dosage form
09/08/2004CN1527699A Stable injecta composition and method
09/08/2004CN1527698A 控释可生物降解的凝胶基质 Controlled release biodegradable gel matrix
09/08/2004CN1527697A Immune modulation device for use in animals
09/08/2004CN1527689A Insert for the treatment of dry eye
09/08/2004CN1527670A Aimal growth regulating composition and its prepn and use
09/08/2004CN1526723A Cholesterin derivative containing azobenzol group and its synthesis and use
09/08/2004CN1526449A Method of eliminating and inhibiting bitter of medicine
09/08/2004CN1526391A Composition containing 5-[4-[2-(N-methyl-N-2-pyridyl)amino oxethyl] benzyl] thiazolidine-2, 4-diketone
09/08/2004CN1165345C Prucalopride oral solution and preparing method thereof
09/08/2004CN1165341C Liquid gonadotropin containing formulations
09/08/2004CN1165340C Cartilage/bone inducing materials for reparation
09/08/2004CN1165339C Pharmaceutical compositions of erythropoietin
09/08/2004CN1165315C Remedies for joint diseases
09/08/2004CN1165309C Stable compositions comprising levosimendan and alginic acid
09/08/2004CN1165307C Controlled release oxycodone compositions
09/08/2004CN1165300C Parenteral paclitaxel stable non-toxic formulation
09/08/2004CN1165297C Composition for transdermal administration
09/08/2004CN1165296C Application of water-soluble or water-dispersible polymerizates which contain poly-ether and which are used as coating agent, binding agent and/or film-forming auxiliary agent
09/08/2004CN1165293C New oral formulation for 5-HT4 agonists or antagonists
09/08/2004CN1165291C Anti-fungus composition with improved biological utilization rate
09/08/2004CN1165290C New medicine release system-liposolubility medicinal preparation
09/08/2004CN1165289C Veterinary formulation for administration of a water-insoluble drug to a target animal through a water distribution system
09/07/2004US6787638 Tumor specific human monoclonal antibodies and methods of use
09/07/2004US6787636 Modified serum albumin with reduced affinity for nickel and copper
09/07/2004US6787572 Use of ubiquinone Q10 for the local treatment and prevention of post-surgical ophthalmologic pathologies
09/07/2004US6787532 Formulation containing anti-inflammatory androstane derivatives
09/07/2004US6787529 Synergistic mixture of vitamin d and corticosteroids; skin disorders
09/07/2004US6787517 Agent and methods for treating pain
09/07/2004US6787342 Paste formulations
09/07/2004US6787335 Polynucleotides and polypeptides which are diagnostic markers for mammary gland cancer.
09/07/2004US6787160 Compositions and methods for high sorption of skin materials and delivery of sulfur
09/07/2004US6787156 Controlled release composition
09/07/2004US6787154 Artificial antigen presenting cells
09/07/2004US6787153 Human monoclonal antibody specifically binding to surface antigen of cancer cell membrane
09/07/2004US6787152 Balancing the molecular properties (van der waals forces and dipole moments) of all the components against those of all the components plus the particular active agent.
09/07/2004US6787149 Topical application of opioid analgesic drugs such as morphine
09/07/2004CA2337015C Excipient
09/07/2004CA2102777C Novel compositions based on taxane class derivatives
09/05/2004CA2428711A1 Formulations and methods of delivery of intact tocopheryl succinate to humans
09/03/2004CA2456410A1 Stabilised pharmaceutical composition comprising an extented release non-steroidal anti-inflammatory agent and an immediate release prostaglandin
09/02/2004WO2004074509A2 Reversible attachment of a membrane active polymer to a polynucleotide
09/02/2004WO2004074437A2 Compositions and methods for cancer immunotherapy
09/02/2004WO2004074434A2 Methods and compositions for administering therapeutic and diagnostic agents
09/02/2004WO2004074345A2 Carbonate esters of polyethylene glycol activated by means of oxalate esters
09/02/2004WO2004074171A1 Method for introducing functional material into organic nanotube